Get the Stockscreener App
4.05
16.05%
0.56
Oragenics Inc stock is traded at $4.05, with a volume of 306.02K.
It is up +16.05% in the last 24 hours and down -29.69% over the past month.
Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013 as a potential treatment of oral mucositis for cancer patients. It also has license agreements with LPThera LLC to develop LPT3-04, a weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
See More
Previous Close:
$3.49
Open:
$3.54
24h Volume:
306.02K
Relative Volume:
1.55
Market Cap:
$3.23M
Revenue:
-
Net Income/Loss:
$-20.26M
P/E Ratio:
-0.4742
EPS:
-8.54
Net Cash Flow:
$-8.25M
1W Performance:
+10.96%
1M Performance:
-29.69%
6M Performance:
-70.23%
1Y Performance:
-86.36%
1-Day Range:
$3.31
$4.19
1-Week Range:
$3.31
$4.19
52-Week Range:
$3.12
$75.60
Oragenics Inc Stock (OGEN) Company Profile
Name
Oragenics Inc
Sector
Industry
Phone
813-286-7900
Address
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Compare OGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
4.05 | 3.23M | 0 | -20.26M | -8.25M | -8.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Oragenics Inc Stock (OGEN) Latest News
Major Shareholder Odyssey Health Sells Oragenics Stock! - TipRanks
Future of Oral Probiotic Supplements | Innovations in Oral - openPR.com
Oragenics Inc. to Showcase Concussion Treatment Candidate at Major 2025 Conferences - citybuzz -
Oragenics to Present at 2025 BIO International Convention and At - GuruFocus
Oragenics, Inc. to Present ONP-002 at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium - Nasdaq
GlobeNewswire by Notified - The Manila Times
Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium | OGEN Stock News - GuruFocus
Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium - The Manila Times
Pre-market Movers: EVGN, WINT, CARM, UNCY... - RTTNews
Oragenics to Present at 2025 BIO International Convention - GlobeNewswire
Top stock gains: US stocks posting the highest gains today - Yahoo
Rocket Lab Corporation (RKLB): A Bull Case Theory - Yahoo
Upstart Holdings, Inc. (UPST): A Bull Case Theory - Yahoo
Vireo Growth Inc. Announces Closing of Proper Brands Acquisition in Missouri - Yahoo
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea - Yahoo
Pre-market Movers: STSS, SGMT, NIVF, OGEN... - RTTNews
Top Premarket Decliners - MarketScreener
Oragenics (OGEN) Resumes Trading: Key Insights for Investors | O - GuruFocus
Oragenics (OGEN) Trading Paused Due to High Volatility | OGEN St - GuruFocus
Oragenics (OGEN) Resumes Trading: Key Insights for Investors | OGEN Stock News - GuruFocus
ABB acquires Bel Products Inc. to expand enclosures portfolio in North America - Yahoo
Pre-market Movers: LYRA, INM, OGEN, VERA... - RTTNews
Oral Probiotics Supplements Gain Popularity in Digestive - openPR.com
OGEN stock touches 52-week low at $0.12 amid sharp annual decline By Investing.com - Investing.com South Africa
OGEN stock touches 52-week low at $0.12 amid sharp annual decline - Investing.com Australia
Oragenics announces reverse stock split to begin June 3 By Investing.com - Investing.com South Africa
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Oragenics (OGEN) Announces One-for-Thirty Reverse Stock Split | - GuruFocus
Oragenics announces reverse stock split to begin June 3 - Investing.com Australia
Oragenics Announces Reverse Stock Split to Boost Share Price - TipRanks
Oragenics (OGEN) Announces One-for-Thirty Reverse Stock Split | OGEN Stock News - GuruFocus
Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split - GlobeNewswire
Worksport Secures ISO 9001 Certification at U.S. Factory, Unlocking Revenue & OEM Growth Pathways - The Manila Times
Oragenics Hosts Neurotrauma Medicine Webinar Presentation - TipRanks
Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com - Defense World
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia - GlobeNewswire
TotalEnergies sells 50% stake in Polish biogas company to HitecVision - Yahoo
Oragenics (OGEN) Gains Approval for Phase II Trial of Neuroprote - GuruFocus
Oragenics gains Australia’s nod for concussion therapy trial - Investing.com Australia
Oragenics gains Australia’s nod for concussion therapy trial By Investing.com - Investing.com Nigeria
Oragenics, Inc. Announces Approval to Initiate Phase II Concussi - GuruFocus
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia | OGEN Stock News - GuruFocus
Oragenics, Inc. to Host Management Update Webinar on May - GlobeNewswire
Oragenics, Inc. to Host Management Update Webinar on May 20, 202 - GuruFocus
Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision | OGEN Stock News - GuruFocus
Oragenics, Inc. to Host Webinar on ONP-002 and Addressing Unmet Needs in Concussion Treatment - Nasdaq
CSW Industrials Announces Date for Fiscal Fourth Quarter and Full Year 2025 Earnings Release Conference Call - The Manila Times
Oragenics: Q1 Earnings Snapshot - New Haven Register
Oragenics Inc Stock (OGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):